摘要
目的探讨血红蛋白(HGB)水平对老年晚期NSCLC患者化疗的预后价值。方法纳入老年NSCLC患者73例,收集患者化疗前HGB水平。HGB水平≤110 g/L为贫血组,否则为正常组。观察两组的近期疗效及远期生存情况。结果贫血组和正常组患者的基线情况相似(P>0.05)。正常组的中位生存时间较贫血组长,且差异达到有统计学意义的趋势(P=0.137)。经过Cox多因素分析,发现HGB水平可能是独立预后因素。结论 HGB水平可能对老年晚期NSCLC患者有潜在的预后判断价值。
Objective To explore the prognostic value of hemoglobin levels in the elderly lung cancer patients after treatment with chemotherapy. Methods We conducted retrospective cohort study of 73 elderly patients with non-small cell lung cancer(NSCLC). The hemoglobin(HGB) was measured before the start of chemotherapy. Patients with HGB level ≤110 g/L were assigned as the anemia group and others were the normal group. The efficacy and long-term survival were retrieved. Results Those with normal(normal group) or low HGB(anemia group) had similar demographic features(P>0.05). Overall survival of normal group was longer than that of anemia group, and the difference showed a tendency toward statistical significance(P=0.137). Multivariate analysis demonstrated a survival advantage for normal group(P= 0.045,HR=0.544,95%CI=0.300-0.985).Conclusion HGB levels have a potential prognostic value for the chemotherapy treatment on elderly advanced NSCLC patients.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2014年第5期401-404,共4页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金资助项目(30901756)
教育部博士点新教师基金资助项目(20090181120100)
